Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
US-11613543-B2 · Mar 28, 2023 · US
Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
US12441733B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12441733-B2 |
| Application number | US-202318169361-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 15, 2023 |
| Priority date | Mar 26, 2018 |
| Publication date | Oct 14, 2025 |
| Grant date | Oct 14, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula (III), Formula (IIIa), Formula (XXIa), Formula (XXIII), or Formula (XLVI): or a salt thereof, wherein: R 6 is H or F; and R 7 is H, F, Cl, CH 3 , OCH 3 , or OCH 2 CH 3 . 2. The compound of claim 1 , wherein the compound has Formula (III): or a salt thereof. 3. The compound of claim 1 , wherein the compound has Formula (IIIa): or a salt thereof. 4. The compound of claim 1 , or a salt thereof, wherein R 6 is H. 5. The compound of claim 1 , or a salt thereof, wherein R 7 is OCH 3 . 6. The compound of claim 1 , wherein the compound is: or a salt thereof. 7. The compound of claim 1 , wherein the compound is: or a salt thereof. 8. The compound of claim 1 , wherein the compound is: or a salt thereof. 9. The compound of claim 1 , wherein the compound is: or a salt thereof. 10. The compound of claim 1 , wherein the compound is: or a salt thereof. 11. The compound of claim 1 , wherein the compound is: or a salt thereof. 12. The compound of claim 1 , wherein the compound is selected from the group consisting of: or a salt thereof.
Assignees
Inventors
Classifications
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Drugs for immunological or allergic disorders · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12441733B2 cover?
- The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the s…
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).